[Practice of hyposensitization in allergic diseases]

Area of Science:

• Immunology
• Allergology

Context:

• Hyposensitization (immunotherapy) is a primary causal treatment for IgE-mediated allergic diseases, alongside allergen avoidance.
• Clinical efficacy of immunotherapy is well-established for allergic rhinitis (hay fever) and allergic asthma, especially in pediatric and young adult populations.
• Immunotherapy demonstrates high effectiveness in managing hymenoptera venom allergies.

Purpose:

• To review the efficacy and practice of allergen immunotherapy for IgE-mediated allergic diseases.
• To highlight the importance of extract quality for diagnosis and treatment success.
• To discuss current therapeutic approaches, including semi-depot and short-term therapies.

Summary:

• Allergen immunotherapy involves administering gradually increasing doses of allergens to induce tolerance.
• High-quality allergen extracts are crucial for accurate diagnosis and optimal treatment outcomes.
• Current practices include semi-depot extracts and newer short-term depot allergoids.
• Careful allergological evaluation, consideration of pollen cross-reactivity, and patient symptom reporting are essential for initiating hyposensitization.
• Patient education on efficacy, treatment duration, and potential side effects is paramount.

Impact:

• Immunotherapy provides a disease-modifying treatment option for allergic conditions.
• Successful immunotherapy can lead to reduced symptoms, medication use, and improved quality of life.
• The availability of standardized and quality-controlled extracts supports widespread clinical application.